Previous article

Pharma & COVID-19: An overview of EU and national case law

The current crisis which has ensued from the spreading of Covid-19 has upset the worldwide balance, seriously straining the entire healthcare system, with significant and inevitable consequences for many other sectors of the economy. Since the very beginning of the state of emergency, the institutions have tried to react by taking measures capable, on the one hand, of tackling the risk of the spread of the pandemic and, on the other, of remedying or avoiding severe repercussions such as, for example, the shortage of essential products, and also of ensuring that those products would be available at competitive prices. In this context, a central role is inevitably played by the pharmaceutical sector, it being the main addressee of the various emergency provisions and measures

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Elisa Teti, Alessandro Raffaelli, Pharma & COVID-19: An overview of EU and national case law, 3 August 2020, e-Competitions Pharma & COVID-19, Art. N° 95938

Visites 472

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues